Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
KEYNOTE-185
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
- NCT02579863 ↗
- Terminated
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on KEYNOTE-185 (pembrolizumab, lenalidomide and 1 more in Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-185 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Naïve Multiple Myeloma (KEYNOTE 185).
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Multiple Myeloma
- Interventions
- Pembrolizumab; Lenalidomide; Dexamethasone
- Arms
- Pembrolizumab + Lenalidomide + Dexamethasone · Experimental
- Lenalidomide + Dexamethasone · Active comparator
- Enrollment
- 310
- Primary outcomes
- Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Oct 19, 2015
- Primary completion
- Jul 9, 2018
- Results posted
- Yes
- Registry record
- NCT02579863 · updated Jul 20, 2021
Publications
linked from the registry- Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J; KEYNOTE-185 Investigators. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18. PubMed 31327689